Kiromic BioPharma (KRBP) Competitors $0.90 +0.08 (+9.70%) As of 01/31/2025 01:19 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends KRBP vs. IMCC, SNPX, BPTH, RNAZ, GTBP, CELZ, PPBT, BNOX, PRTG, and PALIShould you be buying Kiromic BioPharma stock or one of its competitors? The main competitors of Kiromic BioPharma include IM Cannabis (IMCC), Synaptogenix (SNPX), Bio-Path (BPTH), TransCode Therapeutics (RNAZ), GT Biopharma (GTBP), Creative Medical Technology (CELZ), Purple Biotech (PPBT), Bionomics (BNOX), Portage Biotech (PRTG), and Palisade Bio (PALI). These companies are all part of the "pharmaceutical products" industry. Kiromic BioPharma vs. IM Cannabis Synaptogenix Bio-Path TransCode Therapeutics GT Biopharma Creative Medical Technology Purple Biotech Bionomics Portage Biotech Palisade Bio IM Cannabis (NASDAQ:IMCC) and Kiromic BioPharma (NASDAQ:KRBP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment. Does the media prefer IMCC or KRBP? In the previous week, IM Cannabis had 1 more articles in the media than Kiromic BioPharma. MarketBeat recorded 1 mentions for IM Cannabis and 0 mentions for Kiromic BioPharma. IM Cannabis' average media sentiment score of 1.89 beat Kiromic BioPharma's score of 0.00 indicating that IM Cannabis is being referred to more favorably in the media. Company Overall Sentiment IM Cannabis Very Positive Kiromic BioPharma Neutral Do insiders & institutionals have more ownership in IMCC or KRBP? 7.7% of IM Cannabis shares are held by institutional investors. Comparatively, 10.9% of Kiromic BioPharma shares are held by institutional investors. 5.9% of IM Cannabis shares are held by insiders. Comparatively, 20.6% of Kiromic BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer IMCC or KRBP? IM Cannabis received 5 more outperform votes than Kiromic BioPharma when rated by MarketBeat users. However, 50.00% of users gave Kiromic BioPharma an outperform vote while only 42.86% of users gave IM Cannabis an outperform vote. CompanyUnderperformOutperformIM CannabisOutperform Votes642.86% Underperform Votes857.14% Kiromic BioPharmaOutperform Votes150.00% Underperform Votes150.00% Which has better valuation & earnings, IMCC or KRBP? IM Cannabis has higher revenue and earnings than Kiromic BioPharma. IM Cannabis is trading at a lower price-to-earnings ratio than Kiromic BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIM Cannabis$36.15M0.13-$7.04M-$3.41-0.64Kiromic BioPharmaN/AN/A-$20.95M-$6.55-0.14 Which has more risk and volatility, IMCC or KRBP? IM Cannabis has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500. Comparatively, Kiromic BioPharma has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. Is IMCC or KRBP more profitable? Kiromic BioPharma has a net margin of 0.00% compared to IM Cannabis' net margin of -25.55%. Kiromic BioPharma's return on equity of 0.00% beat IM Cannabis' return on equity.Company Net Margins Return on Equity Return on Assets IM Cannabis-25.55% -129.86% -23.63% Kiromic BioPharma N/A N/A -241.14% SummaryIM Cannabis and Kiromic BioPharma tied by winning 7 of the 14 factors compared between the two stocks. Get Kiromic BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for KRBP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRBP vs. The Competition Export to ExcelMetricKiromic BioPharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.23M$3.05B$5.56B$9.10BDividend YieldN/A1.84%5.32%3.99%P/E Ratio-0.1446.5190.3018.28Price / SalesN/A319.021,250.4080.65Price / CashN/A190.0245.9637.70Price / Book-0.124.125.124.70Net Income-$20.95M-$40.99M$111.33M$224.47M7 Day Performance12.49%-0.40%2.32%-0.19%1 Month Performance-0.01%0.96%3.17%0.58%1 Year Performance-28.58%-1.66%24.57%20.27% Kiromic BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRBPKiromic BioPharmaN/A$0.90+9.7%N/A-30.2%$1.23MN/A-0.1460Gap UpIMCCIM Cannabis1.3205 of 5 stars$2.16-2.3%N/A+39.9%$4.82M$51.39M-0.63340Gap UpSNPXSynaptogenix2.3294 of 5 stars$3.51+1.4%$14.00+298.9%-25.3%$4.76MN/A0.004Short Interest ↑BPTHBio-Path2.7961 of 5 stars$0.82-3.0%$20.00+2,326.9%-90.6%$4.76MN/A0.0010Analyst ForecastShort Interest ↓RNAZTransCode Therapeutics3.123 of 5 stars$6.83-3.0%$20.00+192.8%-99.0%$4.75MN/A0.009News CoverageGap DownGTBPGT Biopharma2.7324 of 5 stars$2.04-15.7%$11.00+439.2%-62.5%$4.55MN/A0.008Short Interest ↑Gap DownCELZCreative Medical Technology1.3442 of 5 stars$2.59+6.6%N/A-26.0%$4.53M$10,000.00-0.685Short Interest ↓News CoverageGap UpPPBTPurple Biotech3.0909 of 5 stars$3.40-7.1%$33.00+870.6%N/A$4.52MN/A-0.3920Short Interest ↓BNOXBionomicsN/A$0.25+4.2%$8.00+3,060.8%-73.8%$4.47M$10,000.000.00N/AGap UpHigh Trading VolumePRTGPortage Biotech1.5993 of 5 stars$4.11-2.1%N/A-74.7%$4.32MN/A-0.106Short Interest ↓News CoverageGap UpPALIPalisade Bio3.1716 of 5 stars$1.49-2.0%$23.00+1,443.6%-84.9%$4.12M$250,000.00-0.1110Short Interest ↓Gap Up Related Companies and Tools Related Companies IMCC Competitors SNPX Competitors BPTH Competitors RNAZ Competitors GTBP Competitors CELZ Competitors PPBT Competitors BNOX Competitors PRTG Competitors PALI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KRBP) was last updated on 2/1/2025 by MarketBeat.com Staff From Our PartnersGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredElon’s #1 AI Stock” SET TO SOARForget ChatGPT! Because Elon Musk's AI promises to be 100x more powerful.Behind the Markets | SponsoredWill DeepSeek pop the AI bubble?An overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | SponsoredNow that Trump’s be inaugurated, this day will be key (mark your calendar)Mark your calendar for March 13th. Because on that day, I believe we could see a $2 Trillion shock INTO the...Timothy Sykes | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredDid You See Trump’s Manhattan Project Bombshell?This secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiromic BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiromic BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
